By past MPN Research Foundation grantee (MF Challenge) Pearlie K. Burnette PhD, PharmD, Moffitt Cancer Center The immune system is made up of many types of cells and secreted factors that act together to defend against infections and remove damaged tissues. In the case of cancer, normal cells and cancer cells appear different, and thus,… Read More »IMMUNOTHERAPY: FOCUS AREA THREE
By John D Crispino, PhD, Robert I. Lurie, MD and Lora S. Lurie Professor I’m often asked to explain what exactly is bone marrow fibrosis. In non-technical terms, it is a condition in which the place where blood cell precursors live becomes unfriendly. You can think of the bone marrow niche as a comfortable bed,… Read More »FIBROSIS: FOCUS AREA TWO
September 24, 2014 Dr Angela Fleischman has opened a MPN research laboratory at University of California – Irvine. More information on the lab can be found here. She is looking for help collecting blood samples of MPN patients for a study of the MPN inflammatory processes. If you are an MPN patient in Southern California and are… Read More »SAMPLES SOUGHT BY ANGELA FLEISCHMAN, UC IRVINE
September 18, 2014 Gilead Sciences, Inc is sponsoring a qualitative research study to evaluate the Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) in an electronic format. The study is being conducted by Evidera, Inc., on Gilead’s behalf, and involves the recruitment of up to 25 participants with myelofibrosis.Researchers are currently seeking… Read More »2014 MPN STUDY BY GILEAD AND EVIDERA
September 15, 2014 By Jen, mother of an Essential Thrombocythemia patient This is a tattoo I got for my daughter who has an MPN. Two years ago she was diagnosed with essential thrombocythemia at age five. Despite the shock of the diagnosis, she is a happy seven year old and is doing well. Emotionally, as… Read More »JEN’S CAREGIVER STORY – ET
September 4, 2014 We have been interested in the potential of combination therapy for treatment of MPNs and are pleased to see some initial findings released. Interferon (Pegasys) in combination with Ruxolitinib (Jakafi) was found to have profound effect in the case of a woman with advanced Polycythemia Vera. In an article published by Hans… Read More »STUDY HINTS AT POTENTIAL OF COMBINATION THERAPY FOR POLYCYTHEMIA VERA
September 2, 2014 Promedior, Inc. has been granted orphan drug designation for PRM-151 for the treatment of myelofibrosis by the U.S. Food and Drug Administration (FDA). Click here to read more.
September 1, 2014 I know that it seems like there’s a month or day for everything, from Hamburger Day to Dental Hygienist Appreciation Week, but there are really good reasons to have a month for Blood Cancer Awareness, particularly if you have Polycythemia Vera, Essential Thrombocythemia or Myelofibrosis. There are many people who don’t recognize… Read More »SEPTEMBER IS BLOOD CANCER AWARENESS MONTH
July 31, 2014 The MPN Research Foundation has joined forces with a coalition of patient advocacy organizations who seek to reduce the disparity in copays for people on specialty medication. The initiative, called Cap the Copay, is working to fix what we see as a disparately high copay for people who must take specialty tier medication… Read More »2014 MPNRF JOINS CAP THE COPAY INITIATIVE IN ILLINOIS
